Medicine Press release

Kirin Holdings Company, Limited and Fujitsu Limited have jointly conducted research on food functionality simulation with the goal of creating new functionalities in food.
More info..

Olympus Corporation (Olympus), a global MedTech company committed to making people's lives healthier, safer, and more fulfilling, has announced an additional commitment to its corporate venture capital fund, Olympus Innovation Ventures, LLC (OIV), with the launch of Olympus Innovation Ventures Fund II.
More info..

Olympus Corporation (Olympus), a global MedTech company committed to making people's lives healthier, safer, and more fulfilling, has announced an additional commitment to its corporate venture capital fund, Olympus Innovation Ventures, LLC (OIV), with the launch of Olympus Innovation Ventures Fund II.
More info..

NEC Bio Therapeutics today presents results from the Phase I basket clinical trial of an orally administered cancer vaccine, NECVAX-NEO1, used in combination with checkpoint inhibitors (CPIs) for treating patients with solid tumors.
More info..

NEC Bio Therapeutics today presents results from the Phase I basket clinical trial of an orally administered cancer vaccine, NECVAX-NEO1, used in combination with checkpoint inhibitors (CPIs) for treating patients with solid tumors.
More info..

The inclusion of LEQEMBI in this list marks a meaningful step toward expanding access to early Alzheimer's Disease (AD) treatment in China.
More info..

The inclusion of LEQEMBI in this list marks a meaningful step toward expanding access to early Alzheimer's Disease (AD) treatment in China.
More info..

Eisai Co., Ltd. and Biogen Inc. announced today that the latest findings on time savings with continued treatment with humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody lecanemab (generic name, U.S. brand name LEQEMBI(R)) were presented at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference.
More info..

Eisai Co., Ltd. and Biogen Inc. announced today that the latest findings on time savings with continued treatment with humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody lecanemab (generic name, U.S. brand name LEQEMBI(R)) were presented at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference.
More info..

Eisai Co., Ltd. and Biogen Inc. announced today that the latest data confirming the pharmacological effect of lecanemab, an anti-Aβ protofibril* antibody, on Aβ protofibrils (PF) in cerebrospinal fluid (CSF) was presented at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference.
More info..